1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Medicare Part D Drug Rebate Rule Finally Sees Light Of Day: Now What?

 
• By Cathy Kelly

Assurances from HHS Secretary Azar that rule will not significantly raise premiums and federal spending amount to a request to ‘just trust me.’

Ocean Sunset
Rule Is Released In Waning Days Of The Administration

The risen-from-the-ashes HHS final rule eliminating the anti-kickback safe harbor for manufacturer rebates on prescription drugs was finally released 20 November. It includes some modifications of the proposed version but no new data or analyses supporting US HHS Secretary Alex Azar’s position that the rule will not backfire by significantly increasing plan premiums and federal spending. That raises significant questions about its future.

The rebate rule was announced during a White House event along with an interim final rule much more worrisome to biopharma that would enable the government to test a new Medicare reimbursement policy based on “most favored nation” pricing for Part B drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.